LIVESTRONG SURVEY RESULTS:
Treatment Summaries and Survivorship Care Plans

Since 2005, we have been in the company of advocates who strongly believe that post-treatment cancer survivors should receive a care plan. However, it is still unclear whether care plans improve quality of life or health outcomes, or if survivors even use them once they leave active care. This year, we asked survivors to tell us whether they had received one and if it was useful to them.

**OF THE 213 POST-TREATMENT SURVIVORS WHO RESPONDED:**

- **38%** had heard of a survivorship care plan.
- **29%** received a written summary of their cancer treatments.
- **17%** received a full care plan.
- **94%** found it easy to understand.
- **90%** were satisfied.
- **75%** found it useful.
- **58%** use it to understand long-term effects they might experience.
- **58%** use it to know what healthy behaviors could help reduce risk for recurring and new cancers.
- **53%** use it to know what cancers they should be tested for.
- **68%** use it to understand their cancer treatments.
- **61%** use it to know when they should be tested in the future.

**WHAT IS A SURVIVORSHIP CARE PLAN?**
For post-treatment cancer survivors, a care plan can include a treatment summary, possible future side effects or symptoms, details about when to return and whom to see for checkups, tests and information about healthy living.

**HOW CAN I GET A CARE PLAN FOR MYSELF OR MY LOVED ONES?**
Our free, online survivorship care plan tool allows patients, providers and survivors to enter basic diagnosis and treatment information and generate an individualized care plan. Learn more at LIVESTRONGCareplan.org.

*From 38 respondents who received a care plan.

Since 2006, our surveys have been the core of our work. We learn from cancer patients, survivors, caregivers and their loved ones about their needs and we develop programs and resources to help meet those needs. Learn more at LIVESTRONG.org/LIVESTRONG-Surveys.

This research was made possible by the generous support of Celgene, Genentech, Lilly Oncology, Pfizer Oncology and Taiho Oncology.